Methylnaltrexone
- Generic Name
- Methylnaltrexone
- Brand Names
- Relistor
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26NO4
- CAS Number
- 916055-93-1
- Unique Ingredient Identifier
- 0RK7M7IABE
- Background
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
- Indication
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
- Associated Conditions
- Opioid Induced Constipation (OIC)
- Associated Therapies
- -
Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00936884
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Registration Number
- NCT00858754
- Locations
Pfizer Investigational Site
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT00672139
- Locations
- 🇬🇧
Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom
🇲🇽Pfizer Investigational Site, Mexico City DF, Mexico
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00672477
- Locations
- 🇬🇧
Salix Investigational Site, Cheltenham, Gloucestershire, United Kingdom
🇲🇽Pfizer Investigational Site, Mexico City DF, Mexico
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
- Conditions
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00640146
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc, Tarrytown, New York, United States
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT00401375
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Tarrytown, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.